TRCT
NKTR icon

Tower Research Capital (TRC)’s Nektar Therapeutics NKTR Stock Holding History

Tower Research Capital (TRC)’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$96.8K Sell
1,345
-4,216
-76% -$240K ﹤0.01% 2215
2025
Q4 		$235K Buy
5,561
+5,086
+1,071% +$285K 0.01% 1325
2025
Q3 		$27K Sell
475
-4,949
-91% -$164K ﹤0.01% 3039
2025
Q2 		$140K Buy
5,424
+4,429
+445% +$49.7K ﹤0.01% 2098
2025
Q1 		$10.2K Buy
995
+220
+28% +$2.87K ﹤0.01% 3671
2024
Q4 		$10.8K Sell
775
-417
-35% -$7.35K ﹤0.01% 3774
2024
Q3 		$23.2K Buy
1,192
+577
+94% +$11K ﹤0.01% 3158
2024
Q2 		$11.4K Buy
+615
New +$13K ﹤0.01% 4082
2024
Q1 		– Sell
-686
Closed -$5.81K – 6051
2023
Q4 		$5.81K Sell
686
-821
-54% -$6.22K ﹤0.01% 4806
2023
Q3 		$13.5K Sell
1,507
-1,547
-51% -$14.9K ﹤0.01% 3788
2023
Q2 		$26.3K Buy
3,054
+317
+12% +$3.38K ﹤0.01% 3140
2023
Q1 		$29K Buy
2,737
+2,018
+281% +$61.1K ﹤0.01% 3039
2022
Q4 		$24K Sell
719
-252
-26% -$12.2K ﹤0.01% 2965
2022
Q3 		$47K Buy
971
+437
+82% +$26K ﹤0.01% 3217
2022
Q2 		$31K Buy
534
+289
+118% +$18.2K ﹤0.01% 3345
2022
Q1 		$20K Sell
245
-72
-23% -$10.7K ﹤0.01% 3537
2021
Q4 		$64K Sell
317
-459
-59% -$99.6K ﹤0.01% 2570
2021
Q3 		$209K Sell
776
-3
-0.4% -$721 0.01% 1784
2021
Q2 		$201K Buy
779
+126
+19% +$34.9K 0.01% 1920
2021
Q1 		$196K Sell
653
-372
-36% -$116K ﹤0.01% 2026
2020
Q4 		$261K Buy
1,025
+645
+170% +$167K 0.01% 1505
2020
Q3 		$95K Sell
380
-3,413
-90% -$1.07M ﹤0.01% 3184
2020
Q2 		$1.32M Buy
3,793
+3,735
+6,440% +$1.17M 0.05% 368
2020
Q1 		$16K Sell
58
-556
-91% -$172K ﹤0.01% 1823
2019
Q4 		$199K Buy
614
+36
+6% +$10.4K 0.02% 585
2019
Q3 		$158K Buy
578
+564
+4,029% +$207K 0.01% 1111
2019
Q2 		$8K Sell
14
-553
-98% -$277K ﹤0.01% 2696
2019
Q1 		$285K Buy
567
+288
+103% +$171K 0.02% 965
2018
Q4 		$138K Buy
+279
New +$168K 0.01% 827
2018
Q3 		– Sell
-121
Closed -$89K – 4095
2018
Q2 		$89K Buy
+121
New +$140K 0.01% 1506
2017
Q4 		– Sell
-1,128
Closed -$406K – 3838
2017
Q3 		$406K Buy
+1,128
New +$353K 0.03% 330
2017
Q2 		– Sell
-7
Closed -$2K – 3198
2017
Q1 		$2K Sell
7
-60
-90% -$13.5K ﹤0.01% 2645
2016
Q4 		$12K Buy
+67
New +$13.6K ﹤0.01% 2535
2016
Q2 		– Sell
-57
Closed -$12K – 4791
2016
Q1 		$12K Buy
+57
New +$10.9K ﹤0.01% 1769
2015
Q4 		– Sell
-213
Closed -$35K – 4859
2015
Q3 		$35K Buy
213
+203
+2,030% +$35.9K ﹤0.01% 1275
2015
Q2 		$2K Buy
+10
New +$1.72K ﹤0.01% 3764
2015
Q1 		– Sell
-78
Closed -$18K – 4751
2014
Q4 		$18K Sell
78
-965
-93% -$206K ﹤0.01% 1672
2014
Q3 		$189K Buy
+1,043
New +$200K 0.02% 550
2014
Q2 		– Sell
-266
Closed -$48K – 4441
2014
Q1 		$48K Sell
266
-6
-2% -$1.19K 0.01% 1120
2013
Q4 		$46K Sell
272
-414
-60% -$66.8K 0.01% 1456
2013
Q3 		$108K Buy
+686
New +$127K 0.01% 1222

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Tower Research Capital (TRC)'s NKTR Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Nektar Therapeutics (NKTR) stake by 76% in Q1 2026, selling an estimated $240K and leaving 1,345 shares worth $96.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2215.

Tower Research Capital (TRC) first reported a position in NKTR in Q3 2013 and has held it in 41 quarters since. The position peaked at $1.32M in Q2 2020. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Tower Research Capital (TRC) held 1,345 shares of Nektar Therapeutics worth $96.8K as of Q1 2026.
  • Tower Research Capital (TRC) sold 4,216 Nektar Therapeutics shares in Q1 2026, an estimated $240K.
  • Nektar Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2215 holding.
  • Tower Research Capital (TRC) first reported a position in Nektar Therapeutics in Q3 2013 and has held it in 41 quarters since.
  • Tower Research Capital (TRC)'s Nektar Therapeutics position peaked at $1.32M in Q2 2020.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.